Agios Pharmaceuticals Inc Price/Book
Cos'è Price/Book di Agios Pharmaceuticals Inc?
Price/Book di Agios Pharmaceuticals Inc è 2.10
Qual è la definizione di Price/Book?
Il rapporto Price to book rappresenta il rapporto tra il valore delle azioni di una società e il valore contabile per azione.
The price to book ratio, or P/B ratio, is a financial ratio used to compare a company's current market price to its book value. It is also sometimes known as a market to book ratio or price to equity ratio. The calculation of a price to book ratio can be performed in two ways. It can be calculated as the company's market capitalization divided by the company's total book value from its balance sheet. It can also be calculated using per-share values and dividing a company's current share price by the book value per share (i.e. its book value divided by the number of outstanding shares).
The P/B ratio varies between industries. The industries that require more infrastructure capital (for each dollar of profit) will usually trade at P/B ratios much lower than, for example, consulting firms. P/B ratios are commonly used to compare banks, because most assets and liabilities of banks are constantly valued at market values. A higher P/B ratio implies that investors expect management to create more value from a given set of assets, all else equal (and/or that the market value of the firm's assets is significantly higher than their accounting value).
P/B ratios do not, however, directly provide any information on the ability of the firm to generate profits or cash for shareholders. This ratio also gives some idea of whether an investor is paying too much for what would be left if the company went bankrupt immediately. For companies in distress, the book value is usually calculated without the intangible assets that would have no resale value. In such cases, P/B should also be calculated on a "diluted" basis, because stock options may well vest on sale of the company or change of control or firing of management.
Price/Book di aziende nel Health Care settore su NASDAQ rispetto a Agios Pharmaceuticals Inc
Cosa fa Agios Pharmaceuticals Inc?
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
Aziende con price/book simili a Agios Pharmaceuticals Inc
- Creative Enterprise ha Price/Book di 2.10
- Firebird Metals Ltd ha Price/Book di 2.10
- Vinci Partners Investments Ltd ha Price/Book di 2.10
- Société Marseillaise du Tunnel Prado Carénage ha Price/Book di 2.10
- Parsons Corp ha Price/Book di 2.10
- Lyxor Index Fund - Lyxor Stoxx Europe 600 Food & Beverage UCITS ETF Acc ha Price/Book di 2.10
- Agios Pharmaceuticals Inc ha Price/Book di 2.10
- Logan Ridge Finance ha Price/Book di 2.10
- OneSpaWorld ha Price/Book di 2.10
- PureTech Health plc ha Price/Book di 2.10
- Sangam (India) ha Price/Book di 2.10
- Alamos Gold ha Price/Book di 2.10
- HireRight Corp ha Price/Book di 2.10